Replies to post #256465 on Biotech Values

[dewophile]

re ENTA slide deck

Slide 18 discussing the pediatric RSV data has a one liner about the recent post hoc analysis that was presented last month:

ReSViNET: Reduced the time to complete symptom resolution

Here is a link to that presentation for anyone who was not aware of this data:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-presents-new-data-zelicapavir-its-n